Whatever name it takes when it goes down in history, the present “information age” will be inextricably linked to AI. It’s been so since around 2008, although popular perception needed time to catch up with the depth of the development.

Nearly 90% of executives leading medical-technology companies see emerging technologies as a top challenge. And they’re struggling to apply these advances not only to their product and service lines but also to their own business operations.

AI, the group wrote, could "usurp the EHR as the most disappointing application of technology within medicine”

AI holds the promise of improving gerontology by making it more predictive, personalized, preventive and participatory. However, to get there, an equal number of pronounced risks must be negotiated.  

Patient-facing healthcare workers are neither softened nor hardened in their attitudes toward clinical decision support powered by AI when it’s instead called “AHI,” for augmented human intelligence.

An AI system trained to supply clinical decision support in the U.S. has proven adaptable for physicians treating patients with lung cancer on the other side of the globe.

The vast majority of patients with suspected melanoma—94%—would welcome the use of AI as an augmenter of their dermatologist’s diagnostic skills. And more than 40% would trust their diagnosis to a standalone AI system.  

The solution, Caption AI, was designed to help users “without lengthy specialized training” capture high-quality images.